Acarix announces final outcome of rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAP...
Acarix publish supplement to prospectus
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAP...
The guarantee consortium is expanded to cover approximately 62% of the ongoing rights issue in Acarix
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAP...
Acarix secures insurance coverage in Texas and receives first CADScor®System order
Acarix, a leader in acoustic and AI-based cardiac diagnostics, confirms insurance coverage for the CADScor®System by key payors in ...
Acarix receives additional orders of CADScor®System in Louisiana, USA
Acarix, a leader in acoustic and AI-based cardiac diagnostics, announces today that the company has received additional orders for the ...
Acarix publishes prospectus in connection with the company’s rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAP...
Announcement from Acarix’s extra general meeting
The extra general meeting of Acarix AB ("Acarix" or the "Company") was held today on 9 December 2022 and the following resolutions were...
Acarix to present at the 2022 Nordic American Life Science Conference
Acarix, a leader acoustic and AI-based cardiac diagnostics announces that the company will present at the 7th Annual Nordic American Li...
Notice of Extra General Meeting in Acarix AB
The shareholders of Acarix AB, reg. no. 559009-0667, (the "Company"), are hereby convened to the extra general meeting to be held on Fr...
Acarix resolves on a partially guaranteed rights issue of approximately SEK 52.9 million
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, A...
Acarix presents at Redeye Life Science Day 2022
On November 24th at 14.50 CET Helen Ljungdahl Round, CEO of Acarix, will discuss the latest developments in the company in an in-depth ...
Full focus on the US market with strong interest from healthcare providers, reimbursement code in place and collaboration with ACC
Acarix is now taking an important strategic step, putting full commercial focus on the US market. We have the key building blocks in pl...